PharmaCyte Biotech
PMCB
28 hedge funds and large institutions have $2.02M invested in PharmaCyte Biotech in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 3 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
0.67% more ownership
Funds ownership: 11.55% → 12.22% (+0.67%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
3% less funds holding
Funds holding: 29 → 28 (-1)
13% less capital invested
Capital invested by funds: $2.32M → $2.02M (-$296K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$59.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$59.4K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$29.4K |
| 5 |
Renaissance Technologies
New York
|
+$10.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$51K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$20.3K |
| 3 |
BlackRock
New York
|
-$16.7K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$2.7K |
| 5 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
-$2.05K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Citadel Advisors
Miami,
Florida
| – | -$20.3K | -8,561 | Closed |
|
|
27
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$2.05K | -953 | -100% |
|
28
Wells Fargo
San Francisco,
California
| – | -$130 | -55 | Closed |
|
|
PWMG
29
Private Wealth Management Group
Princeton,
New Jersey
| – | -$100 | -42 | Closed |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$226 | +105 | +67% |
|
PMCB Hedge Fund Activity: Q2 2024 in Review
28 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q2 2024, worth a combined $2.02M — down 13% from $2.32M a quarter earlier.
Fund positioning in PMCB was balanced in Q2 2024: 3 funds opened new positions, 3 closed out, 10 added to existing stakes and 8 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $59.8K. The largest seller was Geode Capital Management, cutting an estimated $51K.
- 28 institutional investors held PharmaCyte Biotech (PMCB) as of Q2 2024, down from 29 in Q1 2024.
- Funds reported $2.02M of PharmaCyte Biotech stock for Q2 2024, down 13% quarter-over-quarter.
- 3 funds opened new PharmaCyte Biotech positions in Q2 2024 and 3 closed out, a net change of 0 holders.
- The largest PharmaCyte Biotech buyer in Q2 2024 was Two Sigma Securities, an estimated $59.8K added.
- The largest PharmaCyte Biotech seller in Q2 2024 was Geode Capital Management, an estimated $51K sold.
Based on aggregated 13F filings for Q2 2024.